Turning Point Therapeutics Inc

NASDAQ:TPTX  
46.82
-3.77 (-7.45%)
Products, Strategic Combinations, Regulatory

Turning Point Therapeutics And EQRX Announce Clinical Collaboration To Evaluate Elzovantinib In Combination With Aumolertinib In Patients With EGFR Mutant Met-Amplified Advanced Non-Small Cell L

Published: 10/13/2021 22:32 GMT
Turning Point Therapeutics Inc (TPTX) - Turning Point Therapeutics and Eqrx Announce Clinical Collaboration to Evaluate Elzovantinib in Combination With Aumolertinib in Patients With Egfr Mutant Met-amplified Advanced Non-small Cell Lung Cancer.
Turning Point - Co Will Sponsor and Conduct Phase 1b/2 Clinical Trial to Evaluate Safety, Tolerability and Preliminary Efficacy of Combination Regimen.
Turning Point Therapeutics Inc -under Agreement,co Will Assume All Costs Associated With Trial.
Turning Point Therapeutics Inc - Eqrx Will Provide Aumolertinib at No Cost.